Conditional Global-First Nod For SanBio's Cell Therapy for TBI
But Product Consistency Challenge Looms
SanBio’s lead cell therapy asset has been on a bumpy journey to its global-first approval and while a nod has now come in Japan in a high-need indication, a commercial launch is conditional on additional data to establish product equivalence and manufacturing consistency.
